Oncternal Therapeutics Inc. [NASDAQ: ONCT] closed the trading session at $3.36 on 11/05/20. The day’s price range saw the stock hit a low of $1.64, while the highest price level was $4.43. The company report on November 5, 2020 that Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update.
Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing sarcoma.
Interim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing sarcoma demonstrated two complete responses, with no relapses after complete response.
The stocks have a year to date performance of -14.94 percent and weekly performance of 116.77 percent. The stock has been moved at 38.27 percent over the last six months. The stock has performed 89.83 percent around the most recent 30 days and changed 19.15 percent over the most recent 3-months.
If compared to the average trading volume of 84.50K shares, ONCT reached to a volume of 86085156 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Oncternal Therapeutics Inc. [ONCT]:
The Average True Range (ATR) for Oncternal Therapeutics Inc. is set at 0.31, with the Price to Sales ratio for ONCT stock in the period of the last 12 months amounting to 26.80. The Price to Book ratio for the last quarter was 5.69.
ONCT stock trade performance evaluation
Oncternal Therapeutics Inc. [ONCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 116.77. With this latest performance, ONCT shares gained by 89.83% in over the last four-week period, additionally plugging by 38.27% over the last 6 months – not to mention a drop of -44.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONCT stock in for the last two-week period is set at 86.28, with the RSI for the last a single of trading hit 91.13, and the three-weeks RSI is set at 79.59 for Oncternal Therapeutics Inc. [ONCT]. The present Moving Average for the last 50 days of trading for this stock 1.90, while it was recorded at 1.91 for the last single week of trading, and 2.74 for the last 200 days.
Oncternal Therapeutics Inc. [ONCT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Oncternal Therapeutics Inc. [ONCT] shares currently have an operating margin of -619.38. Oncternal Therapeutics Inc.’s Net Margin is presently recorded at -1409.81.
Return on Total Capital for ONCT is now -73.97, given the latest momentum, and Return on Invested Capital for the company is -168.77. Return on Equity for this stock declined to -169.15, with Return on Assets sitting at -128.85. When it comes to the capital structure of this company, Oncternal Therapeutics Inc. [ONCT] has a Total Debt to Total Equity ratio set at 1.33. Additionally, ONCT Total Debt to Total Capital is recorded at 1.31, with Total Debt to Total Assets ending up at 0.87. Long-Term Debt to Equity for the company is recorded at 0.64, with the Long-Term Debt to Total Capital now at 0.63.
Reflecting on the efficiency of the workforce at the company, Oncternal Therapeutics Inc. [ONCT] managed to generate an average of -$2,442,000 per employee.Oncternal Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.00.
Earnings per share (EPS) analysis for Oncternal Therapeutics Inc. [ONCT] stock
With the latest financial reports released by the company, Oncternal Therapeutics Inc. posted -0.43/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Oncternal Therapeutics Inc. go to 0.00%.
Oncternal Therapeutics Inc. [ONCT]: Insider Ownership positions
There are presently around $9 million, or 13.60% of ONCT stock, in the hands of institutional investors. The top three institutional holders of ONCT stocks are: ARMISTICE CAPITAL, LLC with ownership of 1,256,717, which is approximately New of the company’s market cap and around 5.70% of the total institutional ownership; CREATIVE PLANNING, holding 487,737 shares of the stock with an approximate value of $1.64 million in ONCT stocks shares; and VANGUARD GROUP INC, currently with $0.96 million in ONCT stock with ownership of nearly -0.121% of the company’s market capitalization.
Positions in Oncternal Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 10 institutional holders increased their position in Oncternal Therapeutics Inc. [NASDAQ:ONCT] by around 1,340,829 shares. Additionally, 7 investors decreased positions by around 9,255 shares, while 9 investors held positions by with 1,351,500 shares. The mentioned changes placed institutional holdings at 2,701,584 shares, according to the latest SEC report filing. ONCT stock had 3 new institutional investments in for a total of 1,256,726 shares, while 4 institutional investors sold positions of 4,320 shares during the same period.